![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Author: Lafuma Antoine Grob Jean Jacques
Publisher: Informa Healthcare
ISSN: 1465-6566
Source: Expert Opinion on Pharmacotherapy, Vol.4, Iss.3, 2003-03, pp. : 343-349
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Adjuvant interferon- -2a of no benefit in malignant melanoma
Inpharma, Vol. 1, Iss. 1306, 2001-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Interferon-α of variable value in melanoma
Inpharma, Vol. 1, Iss. 1599, 2007-01 ,pp. :